How we choose factor VIII to treat hemophilia

Pier Mannuccio Mannucci, Maria Elisa Mancuso and Elena Santagostino

Published e-Letters

Compose eLetter

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests
Publication Date - String
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Enter the characters shown in the image.

Vertical Tabs

  • Risk of variant Creutzfeldt-Jakob disease and ethical considerations in factor VIII choice to treat hemophilia
    • Achille AOUBA, MD
    • Other Contributors:
      • Achille AOUBA, Annie Harroche, Marie-Francoise Torchet, Marie-France Mamzer-Brunel, Chantal Rothschild

    To the Editor. We read with great interest the article by Mannucci et al, who, like the Word Federation of Hemophilia, do not express a preference for recombinant products (RP) over plasma-derived products (PdP) in previously untreated patients (PUPs) with hemophilia 1, 2. This choice is based essentially on a possible lower risk of developing inhibitors and on the currently "impeccable" safety record and lower cost of P...

    Show More
    Conflict of Interest:
    None declared.
  • Treatment of Hemophilia A in countries with limited resources
    • Daniel P. Hart, Senior Lecturer Haematology
    • Other Contributors:
      • Paul Batty and Sean Platton

    As new participants in the World Federation of Hemophilia Twinning program, we have gained a valuable insight into the influence of published medical literature on the global readership. The inherent bias of published manuscripts towards practice in the developed world, pose significant professional and ethical dilemmas for the clinician developing a service in a country with limited resources. Such dilemmas are addressed...

    Show More
    Conflict of Interest:
    None declared.